Monaco Asset Management SAM Takes Position in BioNTech SE Sponsored ADR $BNTX

Monaco Asset Management SAM bought a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,740 shares of the company’s stock, valued at approximately $1,594,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares in the last quarter. Forsta AP Fonden acquired a new stake in shares of BioNTech in the fourth quarter valued at $798,000. SBI Okasan Asset Management Co.Ltd. acquired a new stake in shares of BioNTech in the fourth quarter valued at $352,000. Geode Capital Management LLC increased its stake in shares of BioNTech by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 120,605 shares of the company’s stock valued at $11,482,000 after buying an additional 4,615 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of BioNTech by 3.1% in the fourth quarter. Legal & General Group Plc now owns 321,111 shares of the company’s stock valued at $30,636,000 after buying an additional 9,528 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Price Performance

Shares of BNTX opened at $95.95 on Monday. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The stock has a market cap of $24.26 billion, a P/E ratio of -16.32 and a beta of 1.33. The stock’s 50-day moving average price is $94.46 and its two-hundred day moving average price is $99.45.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The company had revenue of $1.06 billion for the quarter. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -4.71 earnings per share for the current year.

BioNTech declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 4.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the transaction, the chief operating officer owned 399,387 shares in the company, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BNTX. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $117.00 to $135.00 in a research report on Wednesday. Wells Fargo & Company lowered their price objective on BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Citigroup lowered their price objective on BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. TD Cowen lowered their price objective on BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a research report on Wednesday, March 11th. Finally, BMO Capital Markets lowered their price objective on BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $129.56.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.